View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Jean-François Granjon
  • Jean-François Granjon
 PRESS RELEASE

Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris...

Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review PARIS, France, September 12, 2025, 5:45 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today that following the annual review of the Euronext Pa...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch